MyoD binds to Mos and inhibits the Mos/MAP kinase pathway  by Solhonne, Brigitte et al.
MyoD binds to Mos and inhibits the Mos/MAP kinase pathway
Brigitte Solhonne1, Jean Luc Lenormand2, Karine Pelpel, Marie Pierre Leibovitch,
Serge A. Leibovitch*
Laboratoire de Ge¤ne¤tique Oncologique UMR 1599 CNRS, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif, France
Received 27 September 1999
Abstract When ectopically expressed, the serine/threonine
kinase Mos can induce oncogenic transformation of somatic
cells by direct phosphorylation of MAP kinase/ERK kinase
(MEK1), activating the mitogen-activated protein kinases ERK1
and ERK2. On the other hand, overexpression of Mos in C2C12
myoblasts is not transforming. Mos activates myogenic differ-
entiation by promoting heterodimerization of the MyoD/E12
proteins, increasing the expression of myogenic markers and the
positive autoregulatory loop of MyoD. In this study, we show
that in myogenic cells, the mitogenic and oncogenic signalling
from the Mos/MEK/ERK pathway is suppressed by MyoD
through the formation of a heterotrimeric complex.
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1. Introduction
In recent e¡orts to identify and characterize accessory fac-
tors that impinge on MyoD activity, we reported that in
C2C12 myoblasts, ectopic conditional expression of the pro-
tooncogene c-mosrat activated muscle di¡erentiation while in-
hibition of endogenous Mos expression by RNA antisense
resulted in reversible blockage of myogenesis [1], suggesting
that Mos may interact with the muscle regulatory factors.
Indeed, we showed that unphosphorylated MyoD but not
its E12 partner interacts physically with the Mos kinase [2].
Mutational analysis of the proteins demonstrated that a
highly conserved region of Mos proteins that shares sequence
homologies with the ubiquitous E-protein class of b-HLH
associates with the helix 2 domain of MyoD. Furthermore,
phosphorylation of the COOH domain of MyoD by Mos
inhibits the DNA-binding activity of MyoD homodimers
but promotes the formation and DNA-binding activity of
MyoD-E12 heterodimers [2]. Recent data indicated that
Mos favors the capacity of MyoD to up-regulate its own
expression and promotes the levels of MyoD products, sug-
gesting that Mos participates in the positive autoregulation of
MyoD and thus in activation of muscle di¡erentiation [3].
The biological functions of Mos in germ cells correlate well
with the activation of the mitogen-activated protein kinase
(ERKs) [4,5]. Mos associates with and phosphorylates
MEK1 at Ser-218 and Ser-222 to activate MEK1 kinase [6].
Consistent with the persistent ERK activation in Mos-trans-
formed cells, Mos also activates MEK1, suggesting that Mos
may utilize the MEK1/ERK pathway to transform cells. In-
deed, it has been shown that the MEK1/ERK pathway is
essential for oncogenic transformation of NIH 3T3 cells by
Mos [7]. The Mos MAP kinase (MAPK) pathway stabilizes c-
Fos by phosphorylation and augments its transforming activ-
ity in NIH 3T3 cells [8]. In this study, we attempted to eluci-
date the molecular mechanism that leads to the absence of
transformation by Mos in the myogenic cells [2]. We demon-
strate heterotrimeric complex forms between MyoD/Mos/
MEK1 in vitro and in cultured cells. The formation of this
complex suppresses the Mos/MEK/ERK kinase pathway and
could be one of the means by which Mos activity is deviated
from proliferative/transforming genes to di¡erentiating genes
upon early myogenic di¡erentiation.
2. Materials and methods
2.1. Cell cultures, DNA transfections and luciferase assays
The ¢broblastic cell line 10T1/2 was maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 15% fetal
calf serum (FCS). The 10T1/2 cells were transfected using polyethyl-
enimine (Sigma) essentially as described [9]. The total amount of
DNA used for each plate was normalized with the respective empty
expression vector. Forty-eight hours after transfection, cells were har-
vested and luciferase activity determined on aliquots of cell extracts
containing equivalent amounts of proteins with a luminometer (Lu-
mat LB 9507-DLA, Berthold). Plasmid pCH110 (Pharmacia) was in-
cluded in the assays as an internal control for transfection e⁄ciency.
Experiments were performed in triplicate and repeated at least twice.
2.2. Plasmid constructions
Expression vectors pEMSV-MyoD, pGEX2T-Mos wild-type
(Moswt), pCMV-HA-Moswt and pCMV-HA-kinase inactive Mos
(MosKM) were previously described [3]. Plasmids pet-MyoD, pVP16-
MyoD, pVP16-E12, pM-MyoD, pM-Mos and pM-E12 were con-
structed as previously described [2]. pM-MEK1 was generated after
excising the XhoI-PvuII insert from pSp64-MEK1. Insert was ¢lled in
with the Klenow DNA polymerase and inserted in the pM vector
restricted with BamHI, ¢lled in with the Klenow polymerase. These
constructs were controlled by sequencing across the junctions of the
fusion genes.
2.3. Mammalian two and triple hybrid assay
10T1/2 cells were maintained and transfected as described previ-
ously [2]. Then, 4U105 cells were transfected with 2 Wg of the Gal-
dependent reporter plasmid pG5E1b-luciferase and 10 Wg of each of
the indicated plasmids and brought to 25 Wg total DNA with empty
vector. Following transfection, cells were maintained in growth me-
dium for 48 h before harvesting. Luciferase assays were performed as
previously described [2]. Experiments were done in triplicate and re-
peated at least three times.
2.4. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) immunoblotting
Cells were lysed and total proteins solubilized in RIPA bu¡er con-
taining 10 mM EGTA and processed as previously described [10].
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 4 3 0 - 1
*Corresponding author. Fax: (33) (1) 42 11 64 42.
E-mail: leibovit@igr.fr
1 Present address: INSERM U99, Ho“pital Henry Mondor, 94010
Cre¤teil, France.
2 Present address: Laboratoire des Prote¤ines du Cytosquelette, 41,
rue Jules Horowitz, 38000 Grenoble, France.
FEBS 22865 4-11-99
FEBS 22865 FEBS Letters 461 (1999) 107^110
After electrophoretic transfer of proteins onto nitrocellulose mem-
branes, immunodetection was performed with the 12CA5 monoclonal
antibody (dilution: 1/1000, Boehringer) or the MyoD polyclonal anti-
body (dilution: 1/1000, clone C-20, Santa Cruz) or the EKR1/ERK2
polyclonal antibody (1/1000, clone K23, Santa Cruz). After exposure
to the secondary antibody, horseradish peroxidase-linked sheep anti-
rabbit or anti-mouse immunoglobulin G (Sigma), antigen-antibody
complexes were revealed by the enhanced chemoluminescence system
(ECL, Amersham). Exposure was performed with Agfa Curix RP2
¢lms.
2.5. Protein expression, puri¢cation and GST pull-down assay
Bacterial expression of proteins was performed in Escherichia coli
BL21. Protein induction, cell lysis and a⁄nity puri¢cation with glu-
tathione-agarose beads (Sigma) were done as described previously [2].
GST-Moswt fusion protein was not eluted but washed four times at
4‡C in NTEN bu¡er (20 mM Tris pH 8, 100 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40) containing protease inhibitors and phos-
phatase inhibitors. The GST and GST fusion proteins were collected
on glutathione-Sepharose 4B (Pharmacia), analyzed by SDS-PAGE
and their purity was estimated to be 70^80% by Coomassie brilliant
blue staining of the gels. 35S-labelled proteins were prepared by
coupled in vitro transcription-translation using the TnT-coupled rab-
bit reticulocyte lysate system (Promega). GST pull-down assays were
performed as described previously [2]. The programmed lysates (1^9
Wl) were incubated with GST alone and GST fusion proteins for 2 h at
4‡C. Beads were washed four times in NTEN bu¡er at room temper-
ature and then mixed with one volume of 2USDS loading bu¡er and
bound proteins were analyzed by SDS-PAGE by using standard pro-
cedures.
For the competition/association assays, GST-Moswt-covered beads
were ¢rst incubated with 35S-labelled in vitro-translated MyoD or
MEK1 for 2 h at 4‡C and then washed by three wash cycles of bind-
ing bu¡er. Increasing amounts of labelled MyoD or MEK1 were then
added to the binding reactions and the resulting mixtures were sub-
jected to a GST pull-down assay. The reaction products were sepa-
rated on SDS-PAGE. Bound proteins were detected by autoradio-
£uorography and quanti¢ed by using a phosphorimager.
3. Results and discussion
3.1. MEK1 and MyoD physically interact with Mos in
10T1/2 cells
Previous studies have shown that the NH2-terminal domain
of Mos and particularly the Ser-3 is important for Mos inter-
action with MEK1 [11]. On the other hand, a highly con-
served sequence in Mosrat (covering amino acids 184^209),
related to the helix 2 of the E-protein class of b-HLH factors,
mediates interaction with the helix 2 of MyoD [2]. Altogether,
these data indicate that MEK1 and MyoD interact with two
di¡erent domains of Mos. To determine whether MEK1 or
MyoD interaction with Mos is exclusive or not in vivo, we
employed the triple hybrid approach in 10T1/2 cells. We used
the GAL4 DNA-binding domain (DBD)-dependent reporter
system, in which Mos, MEK1 or MyoD (this latter is deleted
of its transcription activation domain to avoid a high back-
ground) were fused to the DBD of GAL4 (pM vector) and
MyoD, E12 or Mos were fused to the VP16 activation domain
(pVP16AD vector). We next introduced into the same 10T1/2
cells, three expression vectors encoding a fusion protein be-
tween the GAL4 DBD and MEK1, a fusion protein between
the VP16 activation domain and Mos and increasing amounts
of pEMSV-MyoD expression vector along with the pG5E1b-
luciferase reporter vector. As illustrated in Fig. 1, expression
of either pM-MyoD, pM-MEK1 or VP16-MyoD, VP16-E12
or VP16-Mos polypeptides failed to induce a signi¢cant lucif-
erase activity in transfected 10T1/2 cells. Co-expression of
pM-MyoD and pVP16-E12 generated a large increase in lucif-
erase activity to levels 500-fold those found with the empty
pM and pVP16AD vectors. These data show that hetero-
dimers are well formed in vivo through a stable interaction
between the b-HLH domains of MyoD and E12. Under the
same conditions, experiments with pM-MyoD, pM-MEK1
and VP16-Mos or VP16-MyoD revealed in vivo association
between Mos and MEK1 (Fig. 1, lane 3), Mos and MyoD
(Fig. 1, lanes 9 and 12), but not with MyoD and MEK1 (Fig.
1, lane 4). Surprisingly, in the presence of increasing amounts
of MyoD, no signi¢cant decrease in luciferase activity was
observed, indicating that interaction between pM-MEK1
and VP16-Mos was not modi¢ed by MyoD (Fig. 1, lanes 5^
8). These data demonstrate the ability of Mos to interact with
MEK1 independently of MyoD and suggest that MyoD does
not suppress Mos-MEK1 interaction although the magnitude
of activation of luciferase activity observed with pM-MEK1
interaction was less than Mos-MyoD. This di¡erence prob-
ably re£ects a surprising weaker a⁄nity between Mos and
MEK1 than Mos and MyoD (compare lanes 3 and 9).
3.2. Interaction between MyoD and Mos is not competed by
MEK1
While MEK1 and MyoD could interact with the NH2 and
COOH domain of Mos, respectively, the experiments de-
scribed above suggest that MyoD and MEK1 could bind in-
dependently to each other with Mos. To test this hypothesis,
we exploited an in vitro association/competition assay. GST-
Mos-covered beads were ¢rst incubated with 35S-labelled in
vitro-translated MyoD for 2 h at 4‡C (Fig. 2A), then, increas-
ing amounts of labelled MEK1 were added to the binding
reactions (Fig. 2A, lanes 9^12) and the resulting mixtures
were subjected to a GST pull-down assay. Increasing amounts
of MEK1 did not a¡ect the level of MyoD bound to GST-
Mos. In the converse experiment, GST-Mos-covered beads
were ¢rst incubated with 35S-labelled in vitro-translated
Fig. 1. Ex vivo interactions between Mos, MyoD and MEK1. 10T1/
2 cells were transiently transfected with 2 Wg of the pG5E1b-lucifer-
ase reporter plasmid and 10 Wg of each expression plasmid. Forty-
eight hours following transfection, cells maintained in DMEM sup-
plemented with 15% FCS were harvested and luciferase activity was
assayed in an aliquot equivalent to 10 Wg of whole cell extracts. Dif-
ferences in transfection e⁄ciencies were corrected based upon the
level of L-galactosidase activity from the co-transfected pCH110
plasmid. Each bar represents the average of at least three independ-
ent transfections.
FEBS 22865 4-11-99
B. Solhonne et al./FEBS Letters 461 (1999) 107^110108
MEK1 (Fig. 2B) and increasing amounts of labelled MyoD
were added to the binding reaction (Fig. 2B, lanes 9^12).
When increasing amounts of MyoD were added to the mix-
ture, GST-Mos-MEK1 complexes were not disrupted (Fig.
2B, lanes 9^12). Even if probably, a portion of GST-Mos is
not fully saturated by MyoD (Fig. 2A) or MEK1 (Fig. 2B)
and can associate with increasing amounts of MEK1 (Fig.
2A) or MyoD (Fig. 2B). Altogether, our results strongly sug-
gest that MEK1 and MyoD do not compete for Mos inter-
action.
3.3. MyoD inhibits Mos-mediated MEK1 and MAPK
activation
To study the e¡ects of MyoD on Mos-mediated MEK and
MAPK activation, we used an in vitro kinase assay. The
translation of mos mRNA in rabbit reticulocyte lysates indu-
ces the phosphorylation and activation of endogenous MAPK
family members, ERK1 and ERK2, detected by their reduced
electrophoretic mobilities on SDS-PAGE (bandshifts) [11,12].
Increasing amounts of puri¢ed bacterially produced MyoD
protein were added to reticulocytes in which Mos protein
was translated. Samples were removed after incubation and
assayed for ERK1 and ERK2 bandshifts by anti-ERK1/
ERK2 immunoblotting. Mos proteins were e⁄ciently trans-
lated and ERK1/ERK2 bandshifts were observed with Moswt
but not with MosKM [2]. In contrast, ERK1 and ERK2 band-
shifts were inhibited in the presence of increasing amounts of
MyoD (Fig. 3, lanes 6^10). The reduction in ERK phospho-
Fig. 2. MyoD does not inhibit MEK1 association with Mos. A:
MyoD and MEK1 were separately in vitro-translated and 5 Wl of
each reaction was pre-incubated with GST alone (lanes 1 and 2) or
GST-Mos fusion protein (lane 7 and 8). Five Wl of MEK1 was also
pre-incubated for 2 h at 4‡C with GST alone (lane 3^6) or GST-
Mos (lane 8^12) and then, 1, 2, 5 and 9 Wl of in vitro-translated
MyoD was added to the binding reaction and incubation was fur-
ther continued for 1 h. After washing, binding proteins were ana-
lyzed by SDS-PAGE and auto£uorography. B: The experiment was
carried out as in A except that 5 Wl of in vitro-translated MyoD
was ¢rst incubated with GST alone or GST-Mos fusion protein.
Then, increasing amounts (1^9 Wl) of in vitro-translated MEK1
were added.
Fig. 3. Inhibitory e¡ect of MyoD on Mos-mediated MAPK phos-
phorylation in vitro. MosKM (lanes 1^5) or Moswt (lanes 6^10) pro-
teins were synthesized in rabbit reticulocyte lysates in the absence
(lanes 1 and 6) or in the presence of increasing amounts of bacteri-
ally produced MyoD (1.5 ng^45 ng/ml) (lanes 2^5 and 7^10) at
30‡C for 1 h. Samples (2 Wl) were analyzed by blotting with anti-
bodies against MyoD or ERK1 and ERK2 MAPKs. In vitro-trans-
lated Mos proteins were detected by SDS-PAGE and autoradiogra-
phy.
Fig. 4. MAPK activity in 10T1/2-mos clones after transfection of
MyoD. A: 10T1/2 cells were stably transfected with pCMC-HA-
Moswt and whole cell lysates (10 Wg) were analyzed by a Western
blot for Mos expression and activation of the MEK/ERK kinase
pathway. B: 10T1/2-mos clones A1 and C2 were transiently trans-
fected with 0.25 and 1 Wg of pEMSV vector (lanes 1 and 2) or 0.25
and 1 Wg of pEMSV-MyoD (lanes 3 and 4). Protein samples were
separated by SDS-PAGE, transferred to nitrocellulose and analyzed
for expression of exogenous HA-Moswt, MyoD and ERK1/ERK2
by Western blots using anti-HA monoclonal antibody, anti-MyoD
or anti-EKR1/ERK2 polyclonal antibodies and visualized by ECL
(Amersham).
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rylation caused by MyoD was not due to a decrease in Mos
translation nor an inhibition in Mos kinase activity as evi-
denced by the reduced mobility of MyoD (Fig. 3, lane 10).
Moreover, we previously showed that MyoD is a substrate for
phosphorylation by the Moswt kinase protein and the ability
of Moswt to phosphorylate MyoD was correlated with the
amount of Mos protein being found in the reticulocyte lysates
[2]. These data strongly suggest that MyoD inhibits Mos-
mediated MAPK phosphorylation by interacting with Mos.
To assay the e¡ect of MyoD on Mos kinase activity in vivo,
Mos was ¢rst transfected in 10T1/2 cells. Stably transfected
cells expressed a biologically active Mos protein as evidenced
by ERK1/ERK2 bandshifts (Fig. 4A). To assess the role of
MyoD in the repression of the Mos/MAPK pathway, the
10T1/2-mos cell lines stably expressing Mos protein (clones
A1 and C2) were transiently transfected with a MyoD expres-
sion vector and the phosphorylation and activation of endog-
enous MAPK family members, ERK1 and ERK2, were de-
tected by their reduced electrophoretic mobilities on SDS-
PAGE. As shown in Fig. 4B, increasing amounts of empty
vector did not modify the Mos-mediated MAPK phospho-
rylation (lanes 1 and 2). In contrast, MyoD repressed
MAPK activation in a dose-dependent manner (lanes 3 and
4) while the expression of Mos was not modi¢ed in both
clones.
In contrast to Ras and Raf oncoprotein transformation that
used multiple signalling pathways [13,14], the MEK1/MAPK
pathway is necessary and su⁄cient for transformation by Mos
[7]. Our results indicate that MyoD is able to form a hetero-
trimeric complex with Mos and MEK1 both in vitro and in
vivo leading to the inhibition of MEK1 kinase. The existence
of this complex could explain how Mos is converted into a
muscle speci¢c regulator on myogenic cell di¡erentiation.
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